Pages that link to "Q45419775"
Jump to navigation
Jump to search
The following pages link to Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study (Q45419775):
Displaying 13 items.
- Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels (Q35669181) (← links)
- Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms (Q38123754) (← links)
- Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders (Q38525979) (← links)
- Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development (Q38790076) (← links)
- Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs (Q44875412) (← links)
- Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives (Q49954326) (← links)
- Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population (Q58779471) (← links)
- Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF. (Q64980635) (← links)
- [Chronic heart failure : current guideline recommendations and innovations] (Q85404538) (← links)
- Management of hypertension in chronic kidney disease (Q85657232) (← links)
- Role of protein kinase C β₂ in relaxin-mediated inhibition of cardiac fibrosis (Q87675503) (← links)
- Sacubitril/Valsartan: potential treatment for paediatric heart failure (Q89443547) (← links)
- Pharmacological interventions for heart failure in people with chronic kidney disease (Q89903377) (← links)